Seven-year median time to progression with thalidomide for smoldering myeloma: Partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Blood

Volumn 112, Issue 8, 2008, Pages 3122-3125

  Barlogie, Bart ^a   Van Rhee, Frits ^a   Shaughnessy Jr , John D ^a   Epstein, Joshua ^a   Yaccoby, Shmuel ^a   Pineda Roman, Mauricio ^a   Hollmig, Klaus ^a   Alsayed, Yazan ^a   Hoering, Antje ^b   Szymonifka, Jackie ^b   Anaissie, Elias ^a   Petty, Nathan ^a   Kumar, Naveen S ^a   Srivastava, Geetika ^a   Jenkins, Bonnie ^a   Crowley, John ^b   Zeldis, Jerome B ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; PAMIDRONIC ACID; THALIDOMIDE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG SENSITIVITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BONE MARROW; DISEASE FREE SURVIVAL; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRECANCER; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; DIPHOSPHONATES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PRECANCEROUS CONDITIONS; SALVAGE THERAPY; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 54049130077     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-164228     Document Type: Article

References (25)

1. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
2. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347-1349.
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
4. Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol. 1997;97:810-814.
5. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94:57-61.
6. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356:2582-2590.
7. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111:785-789.
8. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44. Am J Hematol. 1995;50:9-14.
9. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571.
10. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
11. Folkman J. Angiogenesis-dependent diseases. Semin Oncol. 2001;28:536-542.
12. Rajkumar S, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001; 15:1274-1276.
13. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 1998;187:1885-1892.
14. Berenson JR, Lichenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996; 334:488-493.
15. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
16. Yaccoby S, Barlogie B, Epstein J, et al. Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system [abstract]. Blood. 1998;92:106a.
17. Dhodapkar MV, Singh J, Mehta J, et al. Antimyeloma activity of pamidronate in vivo. Br J Haematol. 1998;103:530-532.
18. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
19. Durie BGM, Harousseau J-L, Miguel JS, etal. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Cox DR. Regression tables and life tables. J Royal Statistical Soc B. 1972;34:187-202.
22. Richardson P, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006; 108:3458-3464.
23. Rajkumar SV, Jacobus S, Callender N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus lowdose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol. 2007;25:968s.
24. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108:2020-2028.
25. Zhan F, Barlogie B, Arzoumanian, et al. Geneexpression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109: 1692-1700.